Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(02): 81-86
DOI: 10.1590/0004-282X20160193
ARTICLES

Neuromyelitis optica: phenotypic characteristics in a Brazilian case series

Neuromielite óptica: características fenotípicas em uma série de casos brasileiros
Maria Cristina Del Negro
1   Rede Sarah de Hospitais de Reabilitação, Serviço de Neurologia, Brasília DF, Brasil;
,
Patricia Beatriz Christino Marinho
1   Rede Sarah de Hospitais de Reabilitação, Serviço de Neurologia, Brasília DF, Brasil;
,
Regina Maria Papais-Alvarenga
2   Universidade Federal do Estado do Rio de Janeiro, Hospital Universitário Gaffrée & Guinle, Serviço de Neurologia, Rio de Janeiro RJ, Brasil.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

The definition of neuromyelitis optica (NMO) is still evolving. In 2015, the International Panel for NMO Diagnosis was convened to develop revised diagnostic criteria. There have been few studies on NMO in the Brazilian population.

Objective

To describe the characteristics of 34 Brazilian NMO patients. To evaluate the contribution of the 2015 criteria to the diagnosis of NMO spectrum disorders (NMOSD) in 40 patients with longitudinal extensive transverse myelitis (LEMT).

Methods

This is a retrospective, descriptive and analytic study.

Results

Among NMO patients, there was a predominance of women, with onset in the fourth decade of life, and AQP4-IgG seropositivity in 73.5%. The diagnosis of NMOSD was established in 37.5% of LETM patients according to AQP4-IgG positivity and in 5% of LETM patients if the AQP4-IgG result was unknown.

Conclusions

The characteristics of this series are similar to those of other Western populations. The AQP4-IgG testing assists in the diagnosis of NMOSD.

RESUMO

Neuromielite óptica (NMO) é um conceito em evolução. Em 2015, o Painel Internacional para o diagnóstico de NMO apresentou novos critérios diagnósticos. Poucos são os estudos em NMO na população brasileira.

Objetivos

Descrever as características de 34 casos brasileiros de NMO. Avaliar a contribuição dos critérios de 2015 para o diagnóstico de desordens do espectro NMO em 40 pacientes com mielite transversa longitudinal extensa (MTLE).

Métodos

Estudo retrospectivo, descritivo e analítico.

Resultados

Predomínio do sexo feminino, início na quarta década e anticorpo anti-AQP4 positivo em 73,5% dos casos de NMO. Diagnóstico de desordem do espectro NMO estabelecido em 37.5% dos casos de MTLE com positividade do anticorpo anti-AQP4 e em 5% se o resultado sorológico fosse desconhecido.

Conclusões

Esta série de casos de NMO tem características semelhantes às de outras séries ocidentais. A pesquisa do anticorpo anti-AQP4 é relevante para o diagnóstico das desordens do espectro da NMO.

neuromyelitis optica - epidemiology - cross-sectional studies - enzyme-linked immunosorbent assay
neuromielite óptica - epidemiologia - estudo transversal - ensaio enzimático


Publication History

Received: 10 June 2015

Accepted: 17 October 2016

Article published online:
05 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10(1):8. http://doi.org/10.1186/1742-2094-10-8
  • 2 O’Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60(4):382-7. http://doi.org/10.1136/jnnp.60.4.382
  • 3 Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53(5):1107-14. http://doi.org/10.1212/WNL.53.5.1107
  • 4 Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12. http://doi.org/10.1016/S0140-6736(04)17551-X
  • 5 Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-7. http://doi.org/10.1084/jem.20050304
  • 6 Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-9. http://doi.org/10.1212/01.wnl.0000216139.44259.74
  • 7 Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-15. http://doi.org/10.1016/S1474-4422(07)70216-8
  • 8 Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. http://doi.org/10.1212/WNL.20160193201601931729
  • 9 Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197-204. http://doi.org/10.1212/WNL.0b013e3182a6cb5c
  • 10 Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010;16(10):1229-36. http://doi.org/10.1177/1352458510376640
  • 11 Lim YM, Pyun SY, Lim HT, Jeong IH, Kim KK. First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci. 2014;35(5):781-3. http://doi.org/10.1007/s10072-014-1635-6
  • 12 Cabre P, González-Quevedo A, Bonnan M, Saiz A, Olindo S, Graus F et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry. 2009;80(10):1162-4. http://doi.org/10.1136/jnnp.2007.143529
  • 13 Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009;256(11):1891-8. http://doi.org/10.1007/s00415-009-5171-x
  • 14 Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurol. 2010;74(9):736-42. http://doi.org/10.1212/WNL.0b013e3181d31e35
  • 15 Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G et al. The prevalence of neuromyelitis optica in south east Wales. Eur J Neur. 2012;19(4):655-9. http://doi.org/10.1111/j.1468-1331.2011.03529.x
  • 16 Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-95. http://doi.org/10.1212/WNL.0b013e3182190f74
  • 17 Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):14. http://doi.org/10.1186/1742-2094-9-14
  • 18 Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80. http://doi.org/10.1001/archneurol.2012.314
  • 19 Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, Almeida AM, Oliveira S, Oliveira CAB et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry. 2002;73(4):429-35. http://doi.org/10.1136/jnnp.73.4.429
  • 20 Alves-Leon SV, Pimentel ML, Sant’anna G, Malfetano FR, Estrada CD, Quirico-Santos T. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr. 2008;66(3B):678-84. http://doi.org/10.1590/S0004-282X2008000500013
  • 21 Adoni T, Lino AM, Gama PD, Apóstolos-Pereira SL, Marchiori PE, Kok F et al. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler. 2010;16(1):81-6. http://doi.org/10.1177/1352458509353651
  • 22 Bichuetti DB, Oliveira EM, Souza NA, Rivero RL, Gabbai AA. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler. 2009;15(5):61-9. http://doi.org/10.1177/1352458508101935
  • 23 Adoni T, Lino AM, Marchiori PE, Kok F, Callegaro D. Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica. Arq Neuropsiquiatr. 2008;66(2B):295-7. http://doi.org/10.1590/S0004-282X2008000300001
  • 24 Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci. 2012;320(1-2):32-7. http://doi.org/10.1016/j.jns.2012.06.002
  • 25 Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665-71. http://doi.org/10.1212/WNL.0b013e318248dec1
  • 26 Isobe N, Yonekawa T, Matsushita T, Kawano Y, Masaki K, Yoshimura S et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler. 2012;18(11):1541-51. http://doi.org/10.1177/1352458512443917
  • 27 Fryer JP, Lennon VA, Pittock SJ, Jenkins SM, Fallier-Becker P, Clardy SL et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflammation. 2014;11(1): e11. http://doi.org/10.1212/NXI.20160193201601930011
  • 28 Lana-Peixoto MA, Talim LE, Faria-Campos AC, Campos SV, Rocha CF, Hanke LA et al. NMO-DBr: The Brazilian Neuromyelitis Optica Database System. Arq Neuropsiquiatr. 2011;69(4):687-92. http://doi.org/10.1590/S0004-282X2011000500021